Kyungpook National University Industry-Academic Cooperation Foundation

Korea Institute of Science and Technology

Arez Co., Ltd.

Jong-Sup Bae

In-San Kim

Gyu Yong Song

Jee Hyun Lee

Doohyun Lee

You-Mie Lee

Jun Young Seo

Kyung-Sik Song

Sae-Kwang Ku

So Youn Kim

Ji-Eun Kim

Taeho Lee

Soo Hyun Cho

Hee Young Won

Wonhwa Lee

Sangkyu Lee

Won Hwa Lee

Kwang-Hyeon Liu

The present invention relates to a composition, for preventing or treating a fine dust-induced respiratory disease, comprising a mixture (Rgx 365), comprising ginsenosides Rg2, Rg4, Rg6 and Rh1, as an active ingredient, a preparation method thereof, and a functional health food, for preventing or relieving a fine dust-induced respiratory disease, comprising same. The present invention exhibits excellent effects on permeability reduction, reactive oxygen (ROS) generation reduction, leucocyte reduction and cytokine generation reduction in a model for fine dust-induced inflammatory response, and thus can be utilized for preventing and treating a fine dust-induced respiratory disease.

Composition for preventing or treating fine dust-induced respiratory disease comprising mixture (RGX-365) comprising ginsenosides RG2, RG4, RG6 and RH1, as active ingredient, and preparation method thereof

The present invention relates to a composition for preventing or treating cancer, a composition for inhibiting the metastasis of cancer, and the like, including TFG nanoparticles or TFMG nanoparticles, and more particularly, to a composition exhibiting effects of treating cancer, effects of inhibiting the metastasis of cancer, and the like by normalizing blood vessels inside a tumor.

Composition for treating cancer or inhibiting cancer metastasis, including TFG or TFMG nanoparticles

The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases. As in the above, the fusion polypeptide, which has an amino acid sequence represented by SEQ ID NO: 1 and in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a fragment of a human-derived ferritin monomer, can fuse two types of anti-inflammatory polypeptides, acting through different mechanisms, into a nano cage and administer the same, and thus the fusion polypeptide can exhibit an excellent effect in the treatment of inflammatory diseases including sepsis.

Fusion polypeptide in which anti-inflammatory polypeptide and ferritin monomer fragment are bound and pharmaceutical composition for preventing and treating inflammatory diseases, containing same as active ingredient

Provided are a pharmaceutical composition containing a 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative represented by Formula 1 as an active ingredient and a use thereof effective on a vascular inflammation-related infectious disease triggered by activity of HMGB1 protein. As investigating an anti-sepsis effect through a CLP-induced sepsis animal test that a sepsis survival rate is increased, it is identified that the pharmaceutical composition contains the 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivative or a pharmaceutically available salt thereof as an active ingredient to be used as a therapeutic agent for a vascular inflammatory disease and infectious disease including sepsis triggered by activity of HMGB1 protein.

2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivatives and use thereof

Growing community of inventors

Daegu, South Korea

Jong-Sup Bae